Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Health Care · ·
$12.28
▲ $0.08 (+0.7%)
Market data updated: 09/21 02:30 PM
Fundamentals updated: 09/20/2026
News analyzed: 09/21/2026
Market Cap
$357.66M
Day Range
$12.12 - $12.28
52-Week Range
$7.05 - $17.15
Beta
—
Next Earnings
16.11.2026
Support
$12.16
Resistance
$15.05
ENTA is a stock from the Healthcare sector — Pharmaceuticals, biotech, medical devices, and health insurance — less sensitive to economic cycles, but exposed to regulation and FDA approvals.
+55.6% (1Y)
Strengths: 6/27 factors positiveRisk: High
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🔴 Bearish
Technical Trend
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Earnings per share (EPS) growth
Earnings per share (EPS) growth: 29.9%
Growth
Biggest negative driver
Operating margin
Operating margin: -130.7% (negative)
Fundamental
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
37
Today
—
30D
—
90D
—
1Y
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
68
Quality
42
Value
55
Momentum
13
Risk
40
Sentiment
32
Fundamental
30
Institutional
No data available
Stocks with a similar DNA right now
Not enough comparably-scored stocks yet to show similar matches.
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Enanta Pharmaceuticals, Inc. has primarily focused on its financial performance and strategic moves. The company reported a missed earnings estimate and increased losses in Q3 2026, with earnings per share at $(0.67) versus the expected $(0.54). Additionally, Enanta raised $75 million through an at-the-market stock offering and is involved in an ongoing patent dispute with Pfizer over Paxlovid, while also participating in investor conferences to discuss its pipeline for viral infections and immunological diseases.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Enanta Pharmaceuticals, Inc.. News trend score: 32. Reason: 4 of the last 12 articles are negative, versus 1 positive.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
26
🎯 Conviction (vs. Emotion)
38
Psychology
93
Fundamentals
30
Technical
13
Valuation
55
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
A sharp drop, unusual volume, and negative news sentiment all at once — selling pressure that looks emotional.
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price (3M)
-4%
Market Narrative
26
Fundamental Reality
38
Narrative Gap
-12
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
ENTA’s psychology is dominated by **FOMO**, as momentum-driven volume and near-overbought conditions align with traders piling in despite modest sentiment. The **overconfidence** score reflects a disconnect between price gains and fundamentals, while **herding** suggests relative underperformance may attract tactical flows. The narrative gap (4 points) hints at a slight misalignment between market expectations and reality, but no extreme bias dominates. The key question: *Will momentum sustain, or will traders pivot as peers recover?*
Updated: 09/09/2026, 09:40 AM
What could change this?
👥 What the crowd believes
"reported quarterly losses of $(0.67) per share which missed the analyst consensus estimate of $(0.54) by 26.42 percent"
"Enanta files appeal in ongoing patent dispute with Pfizer over Paxlovid"
"AbbVie receives European Commission approval of MAVIRET® for acute Hepatitis C Virus"
"Enanta advances RSV drug to Phase 2/3 trial after US FDA meeting"
📈 5D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Benjamin Graham — 100/100
🔴 Weakest match
Jesse Livermore — 12/100
🗣️ Why do they disagree?
The stark divide in verdicts for ENTA reflects a clash between value-driven and growth-oriented philosophies. Benjamin Graham and his enterprising variant all but unanimously endorse the stock as a deep-value opportunity, scoring near-perfectly due to its statistical discount and defensive liquidity. Meanwhile, Walter Bagehot’s endorsement for resilience in a credit crunch further reinforces its appeal to conservative investors. In contrast, methodologies like Philip Fisher and Edgar Lawrence Smith dismiss it outright, as neither sees the sustained quality or stability required for long-term holding. The middle-ground approaches—from Howard Marks’ caution about inflated expectations to Peter Lynch’s mixed assessment—highlight a stock that may have growth but lacks the margin of safety or clear edge to justify aggressive bets. The efficient-market camp and Jack Schwager’s disciplined wizards outright reject the premise of picking it over broader indices, framing it as a speculative rather than systematic choice.
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🟢 100
Attractive to a Defensive Graham Investor
Key question
Where is my margin of safety?
⚠️ Partial data for this stock — score is less reliable — Data availability: 35%
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🟢 100
No obvious signs of crowd mania
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟢 100
Strong liquidity — would likely survive a real credit squeeze
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🟢 100
Deep statistical discount — a real Enterprising Investor candidate
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🟢 95
Cycle position looks favorable — closer to oversold than overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🟢 77
Looks early-to-mid cycle, not overextended
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟢 72
Risk appears reasonably priced — no obvious cycle-timing red flag
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🟡 56
Mixed signal on whether growth translates to real profit
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🟡 56
No clear edge either way
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟡 54
Mixed — growth exists but the price already reflects much of it
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 45
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 39
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 39
Risk profile Loeb would flag as a real threat to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🔴 33
Doesn't show the quality/growth signature Fisher required
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🔴 17
Doesn't show the stability Smith's long-term case requires
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🔴 12
Negative trend — against Livermore's core rule of trading with the trend
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🔴 Most indicators support a downtrend (0 bullish · 10 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a trading range, but the picture isn't yet clear enough on the likely direction.
Low confidence
$12.16
Range Bottom
$15.05
Range Top
50
Trading Days in Range
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
—
Operating Margin
-130.7%
Net Margin
-125.4%
EBITDA Margin
-123.6%
ROE
-126.5%
ROA
-29.2%
ROIC
—
EPS
-$3.84
Cash
$32.30M
Total Debt
—
Current Ratio
4.21
Debt/Equity
—
How is Fair Value calculated? →
Current Price
$12.28
Estimated Fair Value (DCF)
-$19,919.30
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
⚠️ Extreme
Model output is extreme — likely a data/model limitation for this stock, not a reliable fair-value read.
Year 1 Growth Rate
-5.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | -5.0% | $-30.56M | $-28.04M |
| 2 | -3.1% | $-29.60M | $-24.92M |
| 3 | -1.2% | $-29.23M | $-22.57M |
| 4 | 0.6% | $-29.42M | $-20.84M |
| 5 | 2.5% | $-30.15M | $-19.60M |
Base FCF (last actual year)
$-32.17M
Terminal Value
$-475.48M
Present Value of Terminal Value
$-309.03M
Enterprise Value
$-425.00M
Net Debt
$0
Equity Value
$-425.00M
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$3,033.23
Tangible Book Value per Share (Tangible NAV)
$3,033.23
Sentiment based on basic keywords (not AI) — 1 positive, 7 neutral, 4 negative out of the last 12 articles.
Yahoo · 1.9.2026
Business Wire · 1.9.2026
Zacks · 10.8.2026
Associated Press · 10.8.2026
Business Wire · 10.8.2026
Benzinga · 10.8.2026
Zacks · 5.8.2026
MT Newswires · 2.7.2026
Zacks · 24.6.2026
MT Newswires · 24.6.2026
Business Wire · 23.6.2026
MT Newswires · 18.6.2026
Enanta Pharmaceuticals, Inc. (ENTA) currently has a StockIQ AI score of 37/100, rated "Weak". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
ENTA currently scores 37/100 (Weak) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
ENTA's technical score is 13/100, which currently reads as bearish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Earnings per share (EPS) growth: 29.9%; Free cash flow growth: 66.7%; Net income growth: 29.4%.
Based on the real signals StockIQ computed: Operating margin: -130.7% (negative); Net margin: -125.4% (negative); Operating margin is eroding over time.
StockIQ has no recorded dividend payment history for ENTA.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 0 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Rottinghaus Scott T. | Tax Withholding in Shares | 8.8.2026 | 1,467 | -1,467 | $13.34 |
| Rottinghaus Scott T. | Tax Withholding in Shares | 8.8.2026 | 23,787 | -1,467 | $13.34 |
| FOLETTA MARK G | Grant/Award from Employer | 11.3.2026 | 20,000 | +20,000 | — |
| CARTER BRUCE L A | Grant/Award from Employer | 11.3.2026 | 20,000 | +20,000 | — |
| Vance Terry | Grant/Award from Employer | 11.3.2026 | 20,000 | +20,000 | — |
| Russell Lesley | Grant/Award from Employer | 11.3.2026 | 20,000 | +20,000 | — |
| Peterson Kristine | Grant/Award from Employer | 11.3.2026 | 20,000 | +20,000 | — |
| Hata Yujiro S | Grant/Award from Employer | 11.3.2026 | 20,000 | +20,000 | — |
| CARTER BRUCE L A | Grant/Award from Employer | 11.3.2026 | 20,000 | +20,000 | — |
| FOLETTA MARK G | Grant/Award from Employer | 11.3.2026 | 20,000 | +20,000 | — |
| Hata Yujiro S | Grant/Award from Employer | 11.3.2026 | 20,000 | +20,000 | — |
| Peterson Kristine | Grant/Award from Employer | 11.3.2026 | 20,000 | +20,000 | — |
| Russell Lesley | Grant/Award from Employer | 11.3.2026 | 20,000 | +20,000 | — |
| Vance Terry | Grant/Award from Employer | 11.3.2026 | 20,000 | +20,000 | — |
| Or Yat Sun | Grant/Award from Employer | 12.2.2026 | 1,650 | +1,650 | — |
| Rottinghaus Scott T. | Grant/Award from Employer | 12.2.2026 | 1,650 | +1,650 | — |
| Luu Brendan | Grant/Award from Employer | 12.2.2026 | 1,575 | +1,575 | — |
| Kowalsky Matthew Paul | Grant/Award from Employer | 12.2.2026 | 1,318 | +1,318 | — |
| Kieffer Tara Lynn | Grant/Award from Employer | 12.2.2026 | 4,987 | +4,987 | — |
| Rottinghaus Scott T. | Grant/Award from Employer | 12.2.2026 | 5,225 | +5,225 | — |
| Or Yat Sun | Tax Withholding in Shares | 12.2.2026 | 3,413 | -3,413 | $14.25 |
| Luly Jay R. | Tax Withholding in Shares | 12.2.2026 | 6,155 | -6,155 | $14.25 |
| Kowalsky Matthew Paul | Grant/Award from Employer | 12.2.2026 | 4,175 | +4,175 | — |
| Luly Jay R. | Grant/Award from Employer | 12.2.2026 | 15,200 | +15,200 | — |
| Kieffer Tara Lynn | Grant/Award from Employer | 12.2.2026 | 1,575 | +1,575 | — |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
2,616,446 shares short as of 2026-08-31 · vs. 2,587,297 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
56.8% of trading volume this week was short selling, vs. 45.2% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology